Patients with rheumatoid arthritis now often hear doctors say target therapy during treatment and feel some difficulty in understanding and not knowing the specifics. Simply put, target therapy for rheumatoid arthritis is just like our treatment for diabetes blood sugar control and hypertension blood pressure control we should have our goals. So here is a brief introduction to the following: the general principles of “treat to target” (treat to target): (1) patients and physicians make treatment decisions together; (2) the fundamental goals of treatment are to control symptoms, prevent structural damage, restore physiological function and improve daily living ability to maximize health-related life quality of life. (3) The most important way to achieve treatment goals is to clear inflammation, and (4) “target therapy” requires continuous evaluation of disease activity and adjustment of the treatment plan accordingly to maximize the prognosis of patients with rheumatoid arthritis. 10 recommendations for “treat to target”: (1) The primary treatment goal for rheumatoid arthritis is to achieve a state of clinical remission. (2) Clinical remission is defined as the disappearance of significant active signs and symptoms of inflammation. (3) “Remission” should be the fundamental goal, but “low disease activity” may also be an alternative goal for people with long-term disease based on evidence from evidence-based medicine; (4) Treatment regimens should be adjusted at least every 3 months until the desired treatment goal is achieved. (5) Regular evaluation and documentation of disease activity: those with moderate to high disease activity should be evaluated once a month, while those with persistent low activity or persistent remission may be evaluated less frequently, such as once every 3-6 months. (6) In clinical work, a validated comprehensive index of disease activity (which should include joint assessment) such as DAS44, DAS28, SDAI, CDAI, etc. should be used to guide treatment decisions. (7) In addition to disease mobility, structural damage and functional impairment of the joint should be considered when developing a treatment plan, such as an annual joint X-ray or other imaging examinations. (8) After the desired treatment goal has been achieved, subsequent treatment should remain steadfastly adhered to. Discontinuation of disease-modifying drugs during remission can make relapse and re-induction of treatment two times more difficult. (9) Patient comorbidities, their own factors, and drug-related risk factors can influence the choice of a comprehensive assessment tool for disease activity and the level of treatment target values. For example, treatment target values for chronic infections and hepatic and renal insufficiency should be appropriately reduced. (10) Patients must be aware of the treatment goals and implement the “target treatment” program under the supervision of the physician.